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Introduction
Tumor immunotherapies have emerged as first-line treatment for a number of  malignancies (1). In partic-
ular, immune checkpoint blockade (ICB) using anti–PD-1 antibodies (nivolumab or pembrolizumab) has 
demonstrated clinical use in a wide range of  cancer types (1, 2). However, the efficacy of  ICB is currently 
limited to a fraction of  patients with cancer. The preexisting immune composition of  a tumor is a critical 
determinant of  response to ICB, which displays enhanced efficacy in T cell–inflamed tumors (3, 4). In 
addition to their potential as predictive biomarkers for response to ICB therapy, increased densities of  intra-
tumoral CD8+ T cells are associated with enhanced overall survival of  patients with cancer (5). Currently, 
there is an unmet need for therapeutic agents that induce T cell infiltration into tumors and permit effective 
treatment of  patients who exhibit resistance or limited response to ICB.
Myeloid cells comprise several subtypes, including DC and macrophages, which play key roles in reg-
ulating tumor progression and response to therapies (6). Canonically, mature DC are considered immu-
nogenic, while immature DC are deemed to be immunosuppressive (7). In both mice and humans, Batf3- 
dependent conventional type 1 DC (cDC1) are purported to be the primary DC subpopulation responsible 
for the cross-priming of  tumor-specific CD8+ T cells as well as their recruitment to and activation within the 
tumor (8, 9). Consequently, cDC1 are associated with improved response to ICB in melanoma and increased 
patient survival in a variety of  cancer types (9–11). Similar to DC, macrophages, which are among the most 
abundant immune cells in tumors, can play bivalent roles in cancer (12). Depending on their phenotype, 
they are classified as undifferentiated macrophages (M0), classically activated type 1 macrophages (M1), 
Myeloid cells orchestrate the antitumor immune response and influence the efficacy of immune 
checkpoint blockade (ICB) therapies. We and others have previously shown that IL-32 mediates 
DC differentiation and macrophage activation. Here, we demonstrate that IL-32 expression in 
human melanoma positively correlates with overall survival, response to ICB, and an immune-
inflamed tumor microenvironment (TME) enriched in mature DC, M1 macrophages, and CD8+ T cells. 
Treatment of B16F10 murine melanomas with IL-32 increased the frequencies of activated, tumor-
specific CD8+ T cells, leading to the induction of systemic tumor immunity. Our mechanistic in vivo 
studies revealed a potentially novel role of IL-32 in activating intratumoral DC and macrophages 
to act in concert to prime CD8+ T cells and recruit them into the TME through CCL5. Thereby, IL-32 
treatment reduced tumor growth and rendered ICB-resistant B16F10 tumors responsive to anti–PD-1 
therapy without toxicity. Furthermore, increased baseline IL-32 gene expression was associated with 
response to nivolumab and pembrolizumab in 2 independent cohorts of patients with melanoma, 
implying that IL-32 is a predictive biomarker for anti–PD-1 therapy. Collectively, this study suggests 
IL-32 as a potent adjuvant in immunotherapy to enhance the efficacy of ICB in patients with non–T 
cell–inflamed TME.
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and alternatively activated macrophages (M2) (13). Generally, both M0- and M2-like macrophages have 
protumorigenic functions, whereas M1-like macrophages are associated with improved survival (14). While 
DC- and macrophage-targeted agents (e.g., anti-CD40 and poly-ICLC) are being tested in clinical trials, 
none have demonstrated sufficient efficacy to warrant regulatory approval for solid tumors (15, 16).
In our previous work, we discovered an IL-32–dependent pathway of  DC differentiation, and we 
showed that recombinant IL-32γ (here after referred to as IL-32) induces human DC maturation and activa-
tion of  CD8+ T cells in vitro, suggesting its therapeutic potential in cancer (17). The receptor for IL-32 has 
not been identified, and no rodent orthologs of  IL-32 have been reported (18). Consequently, murine studies 
with IL-32 have been limited to transgenic mice overexpressing human IL-32 and to the use of  recombinant 
human IL-32 (19–24). However, IL-32 triggers redundant signaling and effector function in human and 
murine cells (19). IL-32 has pleiotropic functions with 9 known alternative spliced isoforms (18), whereof  
IL-32γ is the largest and, putatively, the most bioactive isoform (25). Each of  these isoforms display differ-
ent activity, and their respective functions have been studied in a number of  diseases, including cancer (22, 
26–28). Studies with murine transgenic models showed that overexpression of  IL-32 (α, β, and γ) inhibited 
the growth of  murine tumors by inducing tumor cell apoptosis, leading to CD8+ T cell responses (21, 22, 29). 
Nevertheless, transgene-induced intracellular expression of  a particular IL-32 isoform may not accurately 
reflect its mechanistic role in human cancers, given that it may not be secreted. Furthermore, it is difficult to 
assess the translational relevance of  IL-32 treatment in these settings. Hence, we investigated the therapeutic 
potential of  intratumoral IL-32γ administration in murine cancer models, while simultaneously assessing the 
immunological correlates and prognostic value of  high IL-32 expression in human melanoma.
Results
IL-32 expression positively correlates with myeloid markers, mature DC, and increased overall survival in patients with 
melanoma. In view of  the previously demonstrated ability of  IL-32 to induce potent DC maturation and mac-
rophage activation, we examined the association between IL-32 and myeloid markers in cutaneous melanoma 
(17). Therefore, we examined the correlation between IL-32 gene expression and the DC marker CD11c (also 
known as ITGAX) as well as the costimulatory molecules CD40, CD80, and CD86 in melanoma samples 
from The Cancer Genome Atlas (TCGA). This analysis revealed a significant, positive correlation between 
IL-32 and genes indicative of  activated myeloid cells (Figure 1A). To comprehensively analyze the association 
between IL-32 expression and mature DC in cancer, we used a previously defined gene signature representing 
“mature DC” to score samples from all TCGA cohorts (30). This revealed a significant positive correlation 
of  IL-32 gene expression to the mature DC signature not only in melanoma, but in all 33 available TCGA 
cohorts (Figure 1B). For further analysis, we stratified melanoma samples from TCGA by IL-32 expression to 
delineate IL-32hi and IL-32lo groups (top and bottom 25%, respectively). Unsupervised clustering analysis con-
firmed enrichment of  genes constituting the mature DC signature in IL-32hi versus IL-32lo melanomas (Figure 
1C). Consequently, IL-32hi samples displayed a significantly higher signature score for DC maturation (Figure 
1D). Due to the indispensable role of  cDC1 in cancer immunity we assessed the relationship between IL-32 
and cDC1 in human melanoma. This analysis revealed a significant positive correlation between IL-32 and a 
previously defined cDC1 gene signature (Figure 1E) (10). These findings provide evidence for a strong associ-
ation of  IL-32 with mature intratumoral DC and increased levels of  cDC1. To assess the prognostic relevance 
of  our findings, we performed Kaplan-Meier survival analysis of  samples from all TCGA cohorts between 
IL-32hi and IL-32lo samples (Supplemental Figure 1A; supplemental material available online with this article; 
https://doi.org/10.1172/jci.insight.138772DS1). The most significant difference in survival between those 2 
groups was observed in patients with melanoma, with the IL-32hi group exhibiting markedly increased surviv-
al (Figure 1F). Furthermore, a multivariate Cox regression analysis revealed IL-32 as a prognostic parameter 
after adjustment for other clinical variables (Table 1). Therefore, IL-32 is a potential prognostic biomarker in 
melanoma; however, this finding requires further validation in a prospective study.
IL-32hi human melanomas exhibit gene signatures associated with T cell activation, M1 macrophage polarization, 
and chemokine activity. Next, we dissected the gene expression profiles of  the previously defined IL-32hi and 
IL-32lo melanoma samples. Unsupervised clustering revealed a distinct transcriptional profile in IL-32hi 
samples compared with that in IL-32lo samples (Supplemental Figure 1B). To delineate biological and 
molecular functions associated with the IL-32hi gene expression profile in melanoma, we performed gene 
ontology (GO) term enrichment analysis. Among the most significantly enriched GO terms by classifica-
tion of  “biological processes” and “molecular functions” were those associated with “T cell activation” 
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and “chemokine activity,” respectively (Figure 2, A and B). Consequently, in IL-32hi biopsies, we detected 
a significantly increased expression of  genes associated with CD8+ effector T cells as well as chemokines 
involved in lymphocyte recruitment and Th1-associated cytokines (Figure 2C) (31, 32). These findings 
suggest that IL-32hi melanomas exhibit a highly chemotactic tumor microenvironment (TME) favoring 
T cell infiltration into the tumor. Therefore, we studied the relationship between IL-32 gene expression 
and tumor-infiltrating immune cells using quanTIseq, a recently described computational approach to 
estimate the relative proportions of  various tumor infiltrating immune cells from bulk tumor RNA-Seq 
profiles (33). This analysis revealed significantly higher proportions of  immune cells in IL-32hi tumors and 
Figure 1. IL-32 expression is associated with activation of myeloid cells and increased overall survival in melanoma. (A) Pearson correlation of IL32 
mRNA expression to that of CD11c (ITGAX), CD86, CD80, and CD40 in melanoma samples from TCGA. (B) Pearson correlation of IL32 gene expression to the 
mature DC score for all available TCGA cohorts. (C) Heatmap of 56 genes defining the mature DC signature, and (D) mature DC score in IL-32lo– and IL-32hi–
expressing melanomas (bottom and top 25%, n = 118). Differences between groups were analyzed by unpaired, 2-tailed Student’s t test. The box extends 
between 25% and 75%, and the whisker extends up to 75% plus IQR and down to 25% minus IQR. (E) Pearson correlation between IL32 mRNA expression 
and gene signature score specific for cDC1. (F) Kaplan-Meier survival curves for IL-32lo (median survival, 701 days) and IL-32hi (mean survival, not applicable) 
patients. (A and F) n = 471 biologically independent melanoma samples from TCGA SKCM cohort. (A, D, and E) Each dot represents an individual patient.
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fewer nonimmune cells (stroma and tumor), relative to IL-32lo melanomas (Figure 2D). To further dissect 
the relative proportions of  immune cell subpopulations, we used CIBERSORT (cell-type identification 
by estimating relative subsets of  RNA transcripts) (34). Importantly, IL-32hi tumors displayed increased 
proportions of  CD8+ T cells and M1 macrophages but reduced M0 (unpolarized) macrophages, relative 
to IL-32lo samples (Figure 2E). DC, which represent a minor fraction of  immune cells in melanoma, were 
largely undetectable by CIBERSORT. In addition, we detected increased frequencies of  tumor-infiltrat-
ing lymphocyte (TIL) in the pathology slides associated with TCGA cutaneous melanoma samples from 
IL-32hi tumors (Supplemental Figure 1C). Collectively, these findings suggest that IL-32 activates DC and 
induces M1 macrophage polarization, leading to the induction of  a chemotactic, T cell–inflamed TME.
IL-32 promotes myeloid cell activation and chemokine activity. To assess the cellular source of  IL-32 with-
in the tumor, we examined previously annotated single-cell RNA-Seq data from patients with melanoma 
(35). IL-32 expression was highest in T lymphocytes and significantly higher in NK and endothelial cells 
compared with cancer cells (Figure 3A). Furthermore, we combined microarray gene expression data sets 
of  9 human hematopoietic cell populations and 63 melanoma cell lines, which confirmed that IL-32 is 
predominantly expressed in certain lymphocyte populations (CD8+ and CD4+ T cells and NK cells) com-
pared with other immune cell subsets or melanoma cell lines (Supplemental Figure 2A) (36, 37). Next, we 
measured IL-32 protein expression in peripheral blood lymphocytes from healthy human donors using 
flow cytometry (Figure 3B). Following activation of  human PBMC in vitro with anti-CD3/CD28 and 
IL-2, intracellular protein expression of  IL-32 significantly enhanced in naive and effector CD8+ and naive 
CD4+ T cells (Figure 3C). These findings were further validated by immunohistochemical labeling of  for-
malin-fixed, paraffin-embedded serial sections of  human melanoma tissue. We observed IL-32 protein in 
lymphocyte-rich regions in close apposition with CD8+ T cells (Figure 3D). A more comprehensive anal-
ysis using multiplex immunofluorescence showed a substantial overlay of  IL-32 with CD3 and CD8 (Sup-
plemental Figure 2B) and a correlation between the percentage of  IL-32+ and CD3+ T cells (Figure 3E). 
Furthermore, IL-32 expression was significantly higher in a group of  long-term survivors as compared 
with that in a group of  short-term survivors (Supplemental Figure 2C). In order to examine the effects of  
IL-32 on the expression of  over 500 immune-related genes in both human melanoma and immune cell 
subsets, we used the NanoString Human Immunology Panel V2. We treated established human melanoma 
cell lines (D10, SK-Mel-37) and multiple FACS-purified immune cell subsets from healthy donor PBMC 
Table 1. Multivariable Cox regression analysis in TCGA cohort
HR (95% CI) P value
IL-32 0.81 (0.75–0.88) <0.0001A
Age 1.00 (1.00–1.00) 0.0187B
Sex
 Female Reference
 Male 0.97 (0.72–1.32) 0.8461
Stage
 0 Reference
 I 0.46 (0.18–1.12) 0.1029
 II 0.37 (0.14–0.94) 0.0373B
 III 0.45 (0.18–1.12) 0.0861
 IV 0.59 (0.20–1.72) 0.3293
 I/I NOS 0.34 (0.10–1.20) 0.0945
Tumor tissue site
 Distant metastasis Reference
 Primary tumor 0.48 (0.29–0.80) 0.0048C
 Regional cutaneous or  
 subcutaneous (including satellite  
 and in-transit metastasis)
0.56 (0.35–0.89) 0.0147B
 Regional lymph node 0.57 (0.38–0.84)
AP ≤ 0.0001; B P ≤ 0.05; C P ≤ 0.01. HR, hazard ratio; NOS, not otherwise specified.
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with IL-32. PCA revealed an altered gene expression profile upon IL-32 treatment in monocytes but not 
in lymphocytes or melanoma cell lines (Figure 3F). To assess the direct downstream signaling of  IL-32 on 
human monocytes, we performed a phospho-kinase array analysis. Phosphorylation was most strongly 
induced on ERK-1/2 (Figure 3G), which was also observed in murine cells (data not shown), indicating 
that IL-32 specifically binds to a receptor, resulting in the downstream activation of  the MAPK/ERK 
pathway in myeloid cells. Furthermore, we detected no direct cytotoxicity of  IL-32 to human and mouse 
Figure 2. IL-32 expression correlates with a T cell–inflamed tumor microenvironment. (A and B) Gene ontology term enrichment analysis of genes upreg-
ulated in IL-32hi melanomas; shown are the top 20 (A) “biological processes” and (B) “molecular functions.” Significantly upregulated genes were identified 
using FDR cutoff of Bonferroni-Hochberg–adjusted P = 0.01 and a log2 fold change = 1. (C) Gene expression of indicated markers for CD8+ effector T cells, 
CD8+ T cell–recruiting chemokines and Th1 cytokines in IL-32lo and IL-32hi melanoma samples. Gene expression is shown as normalized, log2-transformed 
counts. (D) Proportions of immune cells and nonimmune cells (other) in IL-32lo versus IL-32hi tumors, as estimated by quanTiSeq. (E) Relative proportions 
of indicated immune cell subsets in IL-32lo (n = 14) and IL-32hi (n = 101) groups, as estimated by CIBERSORT. (C–E) Data are shown as box-and-whisker plots. 
The box extends between 25% and 75%, and the whisker extends to the minimum and maximum values. Statistical significance was determined by 2-way 
ANOVA followed by Šidák’s multiple comparisons test. (A–D) n = 118; ****P < 0.0001.
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melanoma cells (Supplemental Figure 3A). Ingenuity Pathway Analysis (IPA) revealed the enrichment of  
multiple identical pathways in both human monocytes and murine BMDC treated with IL-32 (Supplemen-
tal Figure 3, B and C). Furthermore, IL-32–matured BMDC displayed significantly elevated mRNA levels 
of  DC maturation markers and T cell–recruiting chemokines (Figure 3H), similar to the gene signature 
associated with IL-32hi human melanomas. Flow cytometric analysis of  IL-32–treated BMDC confirmed 
an increased surface expression of  MHC class I and costimulatory molecules (CD40, CD80) (Figure 3I). 
Accordingly, IL-32–matured BMDC displayed enhanced cross-presentation of  exogenous OVA antigen as 
well as increased MHC-I presentation of  peptide antigen (SIINFEKL) to prime OT-I CD8+ T cells (Figure 
3J). These data are consistent with our previous data showing enhanced CD8+ T cell activation in human 
IL-32–derived DC in vitro (17). Given the increase in M1 macrophage frequencies concomitant with reduc-
tion of  unpolarized M0 macrophages in IL-32hi tumors (Figure. 2E), we also addressed the response of  
bone marrow–derived macrophages (BMDM) to IL-32 using NanoString gene expression profiling. IL-32 
treatment significantly increased the expression of  macrophage activation markers and T cell–recruiting 
chemokines, especially Ccl5 (Figure 3K). Compared with BMDC, IL-32–induced Ccl5 expression was 
more pronounced in BMDM. Taken together, these results suggest that IL-32 is primarily expressed by lym-
phocytes and mediates its effect by triggering the MAPK/ERK pathway in myeloid cells, thereby inducing 
their maturation, activation, and chemokine secretion.
IL-32–treated tumors exhibit increased lymphocyte infiltration and activation of  CD8+ effector T cells. Given our 
findings showing a beneficial role of  IL-32 in human melanoma, we investigated the efficacy of  IL-32 as a 
tumor immunotherapy in mice. As such, we established a standard treatment regimen to evaluate the efficacy 
of  IL-32 in ICB-resistant B16F10 and 4T1 as well as in highly immunogenic MC38 murine syngeneic tumor 
models (Figure 4A) (38–43). Activation of  STING by cGAMP can induce systemic tumor immunity and 
was used as a positive control (44). In the B16F10 model, intratumoral administration of  IL-32 as well as 
cGAMP significantly reduced the tumor growth in the treated primary tumors (Figure 4B) as well as in the 
untreated contralateral tumors (Figure 4C). However, IL-32 treatment was more effective in the contralateral 
tumors, demonstrating its ability to induce potent systemic tumor immunity. Intravenous IL-32 administra-
tion showed a similar effect on tumor growth (Supplemental Figure 5A). Mice treated with IL-32 showed a 
30% prolonged survival compared with PBS, with a median survival of  19.5 and 15 days, respectively (Figure 
4D). We confirmed the therapeutic efficacy of  IL-32 in subcutaneously injected MC38 colon adenocarcino-
mas (Figure 4E) and orthotopically inoculated 4T1 mammary carcinomas (Figure 4F). Flow cytometric pro-
filing revealed a nearly 3-fold increase in CD45+ leukocytes (Figure 4, G and H) as well as CD8+ and CD4+ T 
cell frequencies in IL-32–treated B16F10 tumors (Figure 4I). A similar increase of  CD8+ and CD4+ T cells in 
the TME was observed if  IL-32 was administered systemically (Supplemental Figure 5, B and C). To confirm 
intratumoral T cell recruitment, we performed CD8 immunoperoxidase staining on tissue sections of  B16F10 
tumors. IL-32–treated tumors displayed an approximately 3-fold increase in absolute numbers of  CD8+ T cells 
within the tumor (Figure 4, J and K) as well as significantly increased frequencies of  IFN-γ+ (Figure 4L) and 
Nur77-GFP+ CD8+ T cells (Figure 4M). Taken together, these findings denote significantly enhanced CD8+ 
Figure 3. Lymphocyte-derived IL-32 mediates activation of myeloid but not lymphoid or melanoma cells. (A) IL-32 expression of indicated cell types 
determined by single-cell RNA-Seq data obtained from GSE72056. Data are shown as box-and-whisker plots. The box extends between 25% and 75%, and 
the whiskers extend to the minimum and maximum. Statistical significance was determined using 1-way ANOVA followed by Tukey’s multiple comparisons 
test. (B) Representative histograms of IL-32 expression in indicated immune cell populations from healthy human blood assessed by flow cytometry (n = 
4). (C) IL-32 mean fluorescence intensity (MFI) in each immune cell subset treated for 48 hours with anti-CD3/CD28 and IL-2 or left untreated, (n = 4). (D) 
Representative immunohistochemical labeling for CD8+ T cells (top) and IL-32 (bottom) in serial sections (n = 3). Original magnification, ×5; ×40 (high-mag-
nification images). Scale bars: 200 μm; 20 μm (high-magnification images). (E) Correlation between IL-32+ and CD3+ cells, as assessed by immunofluores-
cence labeling of a melanoma TMA, indicated as a percentage of DAPI+ cells (n = 154; from 140 individual patients) (F) PCA from NanoString-derived gene 
expression profiles of purified human PBMC subsets and melanoma cell lines treated with IL-32 for 24 hours or left untreated (monocytes, n = 4; other PBMC 
subsets, melanoma cell lines, n = 3). Statistical significance was determined using Adonis in the vegan package in R. (G) Kinase phosphorylation levels 
measured by phospho-kinase array in monocytes treated with IL-32 for 20 minutes or left untreated. Two biologically independent samples were measured 
in duplicates. (H) RNA expression levels of the indicated DC maturation markers and chemokines in IL-32–treated (24 hours) and untreated murine BMDC (n 
= 6). (I) MFI of the indicated DC maturation markers assessed by flow cytometry on IL-32–treated versus untreated murine BMDC (n = 4), assessed after 48 
hours. (J) Proliferation of OT-I cells cocultured with IL-32–treated or untreated BMDC after 48 hours measured using a BrdU cell proliferation assay kit (BioVi-
sion). BMDC were either pulsed with OVA protein (left) or SIINFEKL peptide (right) (n = 6). (I and J) Data shown as mean ± SEM; unpaired, 2-tailed Student’s 
t test. (K) Gene expression levels of the indicated macrophage activation markers and T cell–attracting chemokines in murine BMDM treated for 24 hours 
with IL-32 or left untreated, measured by NanoString (n = 6). (H and K) Normalized, log2-transformed mRNA counts shown as box-and-whisker plots. The 
box extends between 25% and 75%, and the whiskers extend to the minimum and maximum. (C, G, H, and K) Statistical significance was determined using 
2-way ANOVA followed by Šidák’s multiple comparisons test. **P < 0.01, ***P < 0.001, ****P < 0.0001.
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T cell activation following IL-32 treatment. Furthermore, TCR clonality was significantly enhanced in the 
tumors, but not in the spleens, of  mice treated with IL-32 (Figure 4N), suggesting the presence of  tumor-reac-
tive T cell clones. In order to determine whether IL-32 treatment resulted in increased tumor antigen-reactive 
CD8+ T cells, we assessed their specificity for MHC class I tetrameric complexes bearing SVYDFFVWL 
peptides derived from tyrosinase-related protein 2 (TRP-2). TRP-2 is a melanocyte-specific antigen in human 
melanoma with a known ortholog in murine B16F10 cells, and CD8+ TIL specific for TRP-2 have been iden-
tified in both humans and mice (45). Indeed, the frequencies of  TRP-2-tetramer–positive CD8+ T cells were 
significantly increased in tumors, but not in the spleens, of  IL-32–treated mice (Figure 4O). To assess whether 
an increase in the frequency of  tumor-reactive CD8+ T cells is essential for IL-32–mediated control of  tumor 
growth, we performed antibody-based depletion of  CD8+ T cells in mice concurrently receiving IL-32. CD8+ 
T cell depletion abolished the efficacy of  IL-32 in both the primary treated tumor and untreated contralateral 
tumor (Figure 4, P and Q). In contrast, IL-32 treatment efficacy was largely independent of  CD4 or NK cells, 
as assessed by CD4 (Figure 4R) and NK depletion (Figure 4S), respectively. Notably, depletion of  CD4 T cells 
is known to reduce the growth of  B16 tumors (46, 47). Collectively, these data show that an increased infiltra-
tion and activation of  CD8+ T cells is indispensable for IL-32–induced tumor control.
IL-32 induces immune cell recruitment and limits tumor growth via the induction of  a chemokine-rich TME. To 
obtain a more comprehensive analysis of  the changes induced by IL-32 within the TME and systemically, 
we analyzed primary B16F10 tumor homogenates and sera from IL-32– and PBS-treated mice for the 
expression of  44 key cytokines and chemokines using an addressable laser bead immunoassay (ALBIA). 
Using hierarchical clustering analysis followed by application of  a threshold to linkage distance, we delin-
eated 5 protein clusters in tumor samples, of  which cluster 1 contained co-upregulated chemokines and 
proinflammatory cytokines in IL-32–treated tumors (Figure 5A). In contrast, there was no difference 
observed in the sera, indicating no induction of  systemic inflammation markers, such as IL-6 and TNF-α 
(Figure 5B). Further dissection of  cluster 1 induced in IL-32–treated tumors showed significantly increased 
protein levels of  the CCR5-binding chemokines CCL3, CCL4, CCL5, and CXCL2 (Figure 5C), corrobo-
rating the observations in IL-32hi human melanoma. To assess the functional relevance of  cross-presenting 
cDC1 in IL-32–induced tumor control, we examined the effects of  IL-32 treatment in B16F10 tumors inoc-
ulated in Batf3–/– mice according to the established treatment regimen (see Figure 4A).
The capacity of  IL-32 to control tumor growth was abrogated in Batf3–/– mice, both in the primary (Figure 
5D) and untreated contralateral tumors (Figure 5E). In addition, IL-32–induced CD8+ T cell infiltration was 
abrogated in Batf3–/– mice (Supplemental Figure 4). However, the differences in CCL5 and CCL4 expression 
between IL-32–treated tumors from WT and Batf3–/– mice were not statistically significant (Figure 5, F and 
G), suggesting that DC are not exclusively responsible for the increased tumor chemokine levels in response 
to IL-32 treatment. In contrast, macrophage depletion using anti-CSF1R antibodies completely abrogated 
IL-32–induced CCL5 but not CCL4 expression (Figure 5, H and I). Together with the results from Figure 
3K, our data suggest that macrophages within the TME secrete CCL5 in response to IL-32. Accordingly, 
the CD8+ T cell infiltration (Figure 5J) and tumor growth reduction (Figure 5K) was lost in the absence of  
macrophages. Since the expression of  CCR5 ligands was significantly associated with IL-32 gene expression 
Figure 4. IL-32 induces a systemic CD8+ T cell–mediated tumor-specific immune response. (A) Experimental setup for in vivo tumor treatments. MC38 
and B16F10 were inoculated in C57BL/6J mice, and 4T1 tumors in BALB/c mice (A–O). (B) Growth curves of IL-32–, cGAMP-, or PBS-treated primary and 
(C) contralateral, nontreated B16F10 melanomas. *P < 0.05, **P < 0.01, ***P < 0.001. Data are representative of 4 independent experiments, with n = 
6 mice per group. (D) Kaplan-Meier survival curves of B16F10-bearing mice treated with IL-32 (n = 6) or PBS (n = 8). (E) Representative growth curves of 
IL-32–treated and untreated MC38 colon adenocarcinoma (n = 6) and (F) orthotopic 4T1 breast tumors (n = 10). (G–O) On day 14, the primary treated tumors 
and spleens were harvested for flow cytometric analyses, IHC or TCRβ chain sequencing. (G) Representative flow cytometry plots displaying frequencies of 
CD45+ immune cells for each treatment group and (H) their quantification shown as relative frequencies (n = 18). (I) Relative frequencies of CD8+ and CD4+ 
T cells as a percentage of live cells (n = 18). (J) Representative immunohistochemical staining and (K) morphometric enumeration as cells/mm2 of CD8+ T 
cells (n = 3). Scale bar: 20 μm. (L) Relative frequencies of IFN-γ+ cells as percentage of CD8+ T cells (n = 12). (M) Frequencies of Nur77-GFP+ cells of CD8+ T 
cells, as determined by flow cytometry in B16F10-inoculated and PBS- (n = 14) and IL-32–treat (n = 13) Nur77 mice. (N) TCR clonality in tumors (left, PBS, n 
= 7; IL-32, n = 5) and spleens (right, PBS, n = 7; IL-32, n = 6), representative of 2 independent experiments. (O) Relative frequencies of TRP-2 tetramer–posi-
tive cells, as a proportion of CD8+ T cells in tumors (left, n = 6) and spleens (right, n = 18). (P) Growth curves of IL-32–treated and untreated B16F10 primary 
tumors (PBS, IL-32, PBS + aCD8, n = 18; IL-32 + aCD8, n = 16) and (Q) untreated contralateral tumors with or without CD8 depletion (n = 16–18). *P = 0.0171; 
**P = 0.003; ****P < 0.0001. (R) Growth curves of IL-32–treated and untreated B16F10 primary tumors with or without CD4 depletion (n = 11) or (S) NK 
depletion (PBS, n = 12; IL-32, n = 18). (B, C, E, F, and P–S) Growth curves are shown as mean ± SEM, using 2-way ANOVA followed by Šidák’s multiple com-
parisons test. (D) Comparison of survival curves was performed using a log-rank (Mantel-Cox) test. (H, I, K–M, and O) Data are displayed as mean ± SEM. 
Statistical significance was determined by unpaired, 2-tailed Student’s t test. ****P < 0.0001.
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Figure 5. IL-32 treatment efficacy relies on the generation a proinflammatory, chemokine-rich TME. (A–I) Mice bearing B16F10 tumors were treated 
with IL-32 or PBS as in Figure 4A. (A–C) At day 12, tumors and spleens were isolated and lysed. Cytokine and chemokine levels were assessed using 
multiplexed bead array (n = 10, from 2 independent experiments). Data are represented as log2(pg/mL). (A) Hierarchical clustering of cytokine protein 
levels in tumor lysates and (B) sera. (C) Protein expression levels of the indicated cytokines and chemokines from tumor lysates, shown as box-and-
whisker plot; the box extends between 25% and 75%, and the whiskers extend to the minimum and maximum values. (D) Growth curves of IL-32– or 
PBS-treated primary (P = 0.2824) and (E) contralateral (P = 0.9859) B16F10 tumors inoculated in Batf3–/– mice. (F) CCL5 and (G) CCL4 expression 
levels in B16F10 tumors at day 12 after tumor inoculation in B6 WT and Batf3–/– mice, as determined by ELISA (PBS, n = 8; IL-32, n = 6). (H–K) IL-32– 
or PBS-treated B16F10 tumors in mice with or without macrophage depletion using anti-CSF1R mAb. (H) CCL5 (PBS, aCSF1R, IL-32 + aCSF1R, n = 11; 
IL-32, n = 10) and (I) CCL4 (PBS, aCSF1R, IL-32 + aCSF1R, n = 12; IL-32, n = 11) expression levels in B16F10 tumors at day 14 after tumor inoculation 
determined by ELISA. (J) Corresponding CD8+ T cell infiltration, as determined by flow cytometry (PBS, aCSF1R, IL-32 + aCSF1R, n = 12; IL-32, n = 10) 
and (K) tumor growth curves (PBS, aCSF1R, IL-32 + aCSF1R, n = 6; IL-32, n = 5). (L and M) CCR5–/– mice (n = 16) were inoculated with B16F10 cells. (L) At 
day 14, tumors were isolated and CD8+ T cell frequencies were determined by FACS. Statistical analysis was performed using 2-tailed Student’s t test. 
(M) Growth curves of IL-32– or PBS-treated B16F10 tumors in CCR5–/– mice (P = 0.9325). (D, E, K, and M) Tumor growth curves are depicted as mean ± 
SEM. Differences between groups were determined using 2-way ANOVA followed by Šidák’s multiple comparisons test. ****P < 0.0001.
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in human melanoma tumors and induced following IL-32 treatment, we investigated the effects of  IL-32 in 
CCR5–/– mice. In the absence of  CCR5, IL-32 treatment did not result in increased frequencies of  CD8+ T cells 
(Figure 5L) and displayed no effects on tumor growth (Figure 5M). These results indicate that IL-32 efficacy is 
predicated on inducing TIL recruitment and thus modulating the immune phenotype of  the TME.
Figure 6. IL-32 treatment is synergistic with concurrent anti-PD1 in mice, and IL-32 expression is predictive for response to anti-PD1 therapy in patients 
with melanoma. (A) Experimental setup for B16F10 dual treatment with IL-32 and anti–PD-1 antibody used in B–D. (B) Tumor growth shown as mean ± 
SEM (IL-32, aPD1, IL-32 + aPD1, n = 23; PBS, n = 24). Statistical significance was determined by 2-way ANOVA followed by Šidák’s multiple comparisons 
test. *P = 0.0199, ****P < 0.0001. (C) Frequencies of CD45+ immune cells and (D) CD4+ T cells and CD8+ T cells as a proportion of viable cells (n = 21–23). P 
values were computed by 1-way ANOVA followed by Tukey’s multiple comparisons test. Data are represented as mean ± SEM. (E) Experimental setup for 
survival and safety assessment with additional IL-32 and anti–PD-1 treatments used for F–J. (F) Kaplan-Meier survival curves. Significance was determined 
by log-rank test (IL-32, IL-32 + aPD-1, n = 15; PBS, n = 17). (G) Body temperature and (H) body weight of mice upon treatment (n = 6). (I) White blood cell 
(WBC), lymphocyte, and red blood cell (RBC) counts as cells/μl blood (n ≥ 4). Blood was obtained when mice were euthanized. Differences between groups 
were determined using 2-way ANOVA followed by Šidák’s multiple comparisons test. (J) IL32 mRNA expression levels in biopsies from patients with mel-
anoma before anti–PD-1 (nivolumab) treatment. (K) IL32 mRNA expression in biopsies of patients with melanoma receiving neoadjuvant pembrolizumab 
treatment (nonrecurrence, n = 8; recurrence, n = 5). The data set was obtained from GSE123728. (J and K) P values were computed by 2-tailed, unpaired 
Student’s t test. Error bars show mean ± SEM. (L) Multivariate logistic regression between response to nivolumab and mRNA expression of the indicated 
genes or mutational load. (J and L) Patients were stratified into responders (complete response and partial response, n = 10) and nonresponders (stable 
disease or progressive disease, n = 39). The data set was obtained from GSE91061.
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IL-32 potentiates the effects of  ICB in mice and is predictive for response to anti–PD-1 therapy in patients 
with melanoma. The increased density of  TIL is generally associated with improved responses to ICB, 
in particular to anti–PD-1 and anti-PDL1 antibodies (48). Due to our results showing that IL-32 
enhanced intratumoral T cell infiltration, we investigated the capacity of  IL-32 to induce responsive-
ness in non-ICB–responding melanomas. Therefore, we established a dual treatment regimen using 
IL-32 and anti–PD-1 in B16F10 tumors (Figure 6A). Mice receiving both IL-32 and anti–PD-1 showed 
significantly reduced tumor growth compared with mice receiving either monotherapy (Figure 6B) and 
displayed the most significant increase in CD45+ leukocytes (Figure 6C). Similarly, the frequencies of  
both CD4+ and CD8+ T cells were most significantly enhanced in the group treated with a combination 
of  IL-32 and anti–PD-1 (Figure 6D). To assess the safety and long-term effects of  IL-32 as single-agent 
treatment and in combination with anti–PD-1 therapy, we established a new treatment schedule (Fig-
ure 6E). The survival rate was significantly improved in mice receiving a combination of  IL-32 and 
anti–PD-1 (median survival, 25 days), which is about a 19% increase compared with IL-32 alone 
(median survival, 21 days), and 56% compared with PBS (median survival, 16 days) (Figure 6F). IL-32 
treatment with or without anti–PD-1 did not result in a significant change of  body temperature (Figure 
6G) or body weight (Figure 6H). Furthermore, white blood cell (WBC), lymphocyte, and red blood 
cell (RBC) counts (Figure 6I) remained constant upon treatment with IL-32 alone or in combination 
with anti–PD-1. Together with the serum cytokine profiling (Figure 5B), these data suggest IL-32 as 
a safe tumor treatment and suggest that it is also safe when combined with anti–PD-1 therapy. Subse-
quently, we analyzed IL-32 gene expression in biopsies from patients with melanoma before treatment 
with anti–PD-1 (nivolumab or pembrolizumab) (49, 50). IL32 mRNA levels were significantly higher 
in anti–PD-1 treatment–responding patients with melanoma or patients with no disease recurrence 
compared with nonresponders or patients with recurrent disease in 2 independent cohorts (Figure 6, 
J and K). Several predictive biomarkers for ICB have been identified, including the tumor mutational 
load, CD8 infiltration, and PD-1 and PD-L1 expression (1). However, none of  these biomarkers are 
truly predictive individually (1, 48), demonstrating the need for additional biomarkers. Here, we com-
pared the predictive potential of  IL-32 to PD-1, PD-L1, CD8B, and the mutational load in pretreatment 
samples from the Nivolumab cohort (49). Intriguingly, IL-32 showed the most significant correlation 
to response, while CD8B expression also reached significance (Figure 6L). Therefore, baseline intratu-
moral IL-32 levels represent a potential predictive biomarker for response to ICB; however, this needs 
further validation. Together, our findings suggest that IL-32 in combination with anti–PD-1 is a viable 
and save strategy for inducing tumor immunity in a wide range of  immune excluded tumor types, 
which fail to respond to ICB monotherapy (3).
Overall, we revealed a detailed mechanism of  action of  IL-32 in melanoma (Figure 7). First, we 
found that IL-32 is primarily expressed in tumor-infiltrating T cells and acts in a paracrine fashion 
on myeloid cells. Specifically, it induced maturation and cross-priming in DC as well as M1 polariza-
tion and CCL5 release in macrophages. Hence, CD8+ T cell infiltration into the TME via CCR5 was 
enhanced, leading to the killing of  cancer cells. Consequently, IL-32 injections reduced the growth 
of  various syngeneic tumors, and IL-32 expression was associated with prolonged overall survival of  
patients with melanoma. Moreover, given the ability of  IL-32 to induce a T cell–inflamed TME, it 
potentiated the response to anti–PD-1 therapy and strongly correlated with response to pembrolizumab 
and nivolumab in patients with melanoma.
Discussion
A T cell–inflamed TME is generally associated with better prognosis as well as improved response to ICB 
(1, 5, 48). In this study, we demonstrate that IL-32 potentiates T cell infiltration into the tumor, leading to 
enhanced survival of  patients with melanoma and response to ICB. Injection of  IL-32 in murine tumors 
induced a systemic, tumor-specific immune response. Furthermore, IL-32 treatment rendered B16F10 
tumors responsive to anti–PD-1 treatment and the combination significantly improved control of  tumor 
growth compared with either monotherapy. Our results indicate that T cell–derived IL-32 acts on DC to 
induce maturation and cross-presentation function, as well as on macrophages to trigger M1 polarization 
and CCL5 expression. Thus, in response to IL-32, DC and macrophages act in concert to prime and recruit 
T cells into the TME. Collectively, these findings provide robust evidence for the therapeutic efficacy of  
IL-32 as a tumor immunotherapy, in particular, for patients whose cancers exhibit immune excluded TME.
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Mature DC and M1-polarized macrophages regulate the antitumor immune response and are positive 
prognostic factors for patients with various cancers (14, 51–53). We show that IL-32 gene expression pos-
itively correlates with mature DC in all 33 examined cancer types from TCGA. In melanoma, increased 
IL-32 expression was also associated with higher levels of  cDC1 and improved overall survival. Notably, 
Batf3-dependent cDC1 are the primary DC population orchestrating the antitumor immune response with-
in the TME (8). Deficiency of  cross-presenting DC (in Batf3–/– mice) or CD8+ T cells abrogated the ther-
apeutic efficacy of  IL-32 in mice, suggesting that the IL-32 effector mechanisms are dependent on cDC1 
priming of  tumor-specific CD8+ T cells. Additionally, we found a positive correlation between IL-32 and 
M1 macrophages concomitant with a negative correlation to M0 macrophages in melanoma, suggesting 
that IL-32 induces both cross-presentation in DC and M1 polarization in macrophages.
While IL-32 is associated with the outcome of  several cancers and plays a role in both inflammatory 
and infectious diseases, its precise cellular source and functions within the TME remain poorly described 
(18). A recent report demonstrated an association between high IL-32 expression and a dedifferentiated 
phenotype in cell lines, but not in samples from patients with cutaneous melanoma (54). This observed 
discrepancy between IL-32 expression in cell lines versus whole tumors may be attributed to the source 
of  IL-32 in human cancers. Our study strongly suggests the primary cellular source of  IL-32 in human 
tumors to be T cells. This may explain the previously noted positive correlation between IL-32 expression 
and individual genes indicative of  lymphocyte infiltration, such as CD3E, CD8A, and IFNG, in bulk tumor 
samples (54). This observation is further corroborated by the initial study describing NK4 (later termed 
IL-32) as a T cell– and NK cell–specific transcript, which was not detected in HeLa carcinoma or HL60 
and K562 myeloid leukemia cell lines (55).
Our results also provide potentially new mechanistic insight into the role of  IL-32, demonstrating that 
myeloid cells but not lymphocytes or cancer cells respond to IL-32 treatment by activating the MAPK/ERK 
pathway, suggesting its binding to a hitherto unidentified surface receptor. Studies addressing the role of  
IL-32 in mice are limited by the fact that no murine homolog has been identified so far (18). However, our 
data derived from gene expression profiling of  IL-32–treated human monocytes and murine BMDC indicate 
redundant functions of  IL-32 in human and mice. In addition to its redundant effector functions, we discov-
ered identical downstream phosphorylation patterns upon IL-32 activation of  murine DC as observed in 
humans. Together, our data suggests that in human melanoma IL-32 is primarily expressed in lymphocytes 
and enhances the activation of  intratumoral myeloid cells in a paracrine fashion. As such, IL-32 represents a 
promising modulator of  intratumoral DC and macrophage function and thus, a potentially novel molecular 
target for myeloid cell–based cancer immunotherapy. Notably, as opposed to studies performed in IL-32–over-
expressing mice, we did not observe any direct cytotoxicity of  IL-32 to tumor cells in vitro (21, 22). This might 
be due to distinct effects of  intracellular IL-32 overexpression versus those of  exogenously added IL-32γ.
Figure 7. Roles of IL-32 in the antitumor immune response. In melanoma, IL-32 is mainly produced by T cells. Injections of IL-32 improve DC function and trig-
ger M1 polarization as well as CCL5 release in macrophages, resulting in CCR5-mediated CD8+ T cell infiltration into the TME and the eradication of cancer cells. 
Accordingly, IL-32 treatment has antitumorigenic functions in murine cancer models and positively correlates with overall survival of patients with melanoma. 
Moreover, it acts synergistically with anti–PD-1 therapy and strongly correlates with response to anti–PD-1 therapy in patients with melanoma.
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CD8+ T cell recruitment to the tumor is governed by multiple chemokines. In melanoma, CD8+ T cell 
infiltration correlates with the expression of  several chemokines, including the CCR5 ligands, CCL4 and 
CCL5, as well as the CXCR3 ligands, CXCL9 and CXCL10 (31). Recent evidence suggests that CCL4 and 
CCL5, but not CXCL9-11, are positively associated with survival in melanoma (56). Our transcriptomic 
analyses of  IL-32hi melanoma samples revealed an enhanced T cell infiltration, likely as a result of  the 
increased levels of  the aforementioned T cell–recruiting chemokines. In line with the human data, the 
most salient feature of  IL-32–treated B16F10 melanomas was a chemokine-rich TME, concomitant with 
enhanced frequencies of  activated, tumor-specific CD8+ T cells, recapitulating the findings from human 
melanoma TCGA samples. Since IL-32 treatment mainly induced CCR5 ligands, we inoculated Ccr5-de-
ficient (Ccr5–/–) mice with B16F10 melanomas. Ccr5 deficiency abrogated the IL-32–mediated CD8+ T cell 
infiltration and its therapeutic effect, i.e., tumor growth reduction, highlighting the induction of  T cell–
recruiting chemokines as a key effector mechanism of  IL-32 in tumor immunity. Our data are supported 
by earlier in vitro observations that IL-32–treated murine BMDC upregulate a number of  chemokines, in 
particular CCL5, and can induce migration of  activated CD4+ and CD8+ T cells in vitro (24). Notably, we 
found that the induction of  chemokine expression in response to IL-32 was mainly dependent on macro-
phages, as macrophage depletion completely abrogated the induction of  CCL5 upon IL-32 treatment.
A preexisting tumor-specific T cell response is a critical determinant of  the patient survival and response 
to ICB (1, 5). However, the TME is often highly immunosuppressive, with several mechanisms preventing 
infiltration and activation of  tumor-specific CD8+ T cells (57). As such, ICB is currently being tested in 
combination with a number of  additional TME-modulating therapies, including proinflammatory cytokines 
(58). Here, we show for the first time to our knowledge that direct administration of  IL-32 leads to increased 
frequencies of  tumor-infiltrating T cells in multiple poorly immunogenic mouse tumor models. Thus, IL-32 
in combination with ICB may be a viable therapeutic strategy for ICB-resistant patients with non–T cell–
inflamed tumors (4). Our data provide proof  of  concept for this approach, with no detectable immune-relat-
ed toxicity in these animals. In addition, our data suggest that IL-32 gene expression could delineate patients 
with melanoma who respond to nivolumab or pembrolizumab, highlighting its potential use as a predictive 
biomarker for response to anti–PD-1 therapy. While additional studies are required to validate IL-32 as a 
predictive or prognostic biomarker and to translate IL-32 as a tumor immunotherapy to the clinic, the thera-
peutic efficacy of  this cytokine for melanoma treatment has been demonstrated in this study.
Methods
Tissue culture. Murine B16F10 melanoma and 4T1 breast carcinoma cell lines were purchased from ATCC. 
The MC38 colon adenocarcinoma cell line was provided by A. Zippelius (Department of  Biomedicine, Uni-
versity of  Basel, Basel, Switzerland). Human SK-MEL-37 and D10 melanoma cell lines were a gift from P. 
Zajac (Department of  Biomedicine, University of  Basel). All murine cell lines were cultured in complete 
RPMI-1640 medium (MilliporeSigma; supplemented with 10% FBS, 100 units/mL penicillin, 100 μg/mL 
streptomycin, 1 mM sodium pyruvate, and 2 mM L-glutamine). Human melanoma cell lines were grown in 
complete DMEM (MilliporeSigma; supplemented with 10% FBS, 100 units/mL penicillin, 100 μg/mL strep-
tomycin, 1 mM sodium pyruvate, and 2 mM L-glutamine). Primary murine cells, such as splenocytes and 
T lymphocytes and human PBMC, were cultured using complete RPMI-1640 medium as described above.
BMDC maturation and T cell proliferation assays and BMDM activation. To generate murine BMDC or 
BMDM, bone marrow was flushed from femurs and tibias of  C57BL/6J (B6) mice and cultured in 
Petri dishes at 5 × 106 cells per dish using complete RPMI-1640, supplemented as described above and 
containing 10 ng/mL GM-CSF (MilliporeSigma) or M-CSF (culture medium supplemented with 20% 
L929 supernatant), respectively. GM-CSF or M-CSF were replaced on day 4. After 1 week, cells were 
harvested and BMDC were further purified using magnetic anti-CD11c microbeads (Miltenyi Biotec). 
Purified CD11c+ murine DC or BMDM were seeded into 6-well plates and matured with 200 ng/mL 
human IL-32 (R&D Systems) for 48 hours. DC were pulsed with 1 mg/mL OVA (EndoFit Ovalbumin, 
InvivoGen) or 1 nM SIINFEKL (MilliporeSigma) antigen for 24 hours. Subsequently, CD8+ T cells 
were purified from the spleens of  OT-I mice using EasySep Mouse CD8+ T cell Isolation Kit (negative 
selection, STEMCELL Technologies) and cocultured with matured CD11c+ DC. T cell proliferation was 
assessed after 48 hours using the BrdU Cell Proliferation Assay Kit (BioVision). Purified IL-32γ matured 
CD11c+ DC and BMDM as well as untreated controls were also transcriptionally profiled after 24 hours 
using NanoString and analyzed via flow cytometry after 48 hours.
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Monocyte isolation and differentiation. For human monocyte mRNA profiling via NanoString, blood was 
obtained from healthy volunteers (Interregionale Blutspende SRK). PBMC were isolated using Ficoll (GE 
Healthcare) and enriched for monocytes using the EasySep Human Monocyte Enrichment Kit without 
CD16 Depletion (STEMCELL Technologies). Purified monocytes were treated with 200 ng/mL human 
IL-32 (R&D Systems) for 24 hours or left untreated.
Mice, tumor inoculation, and in vivo studies. B6 and BALB/cJ mice were purchased from Janvier Labs 
(France). Batf3-deficient (Batf3–/–) mice on a B6 background, generated as previously described (59), were 
obtained from M. Suter (Department of  Research, Bavarian Nordic GmbH, Martinsried, Germany; Uni-
versity of  Zurich, Zurich, Switzerland). OT-I–transgenic mice (TgTcraTcrb)1100Mjb (60), were obtained 
from University of  Zürich (Animal Management System – iRATS). CCR5–/– mice on a B6 background 
were obtained from The Jackson Laboratory. Nur77-GFP mice (Tg(Nr4a1-EGFP/cre)820Khog/J) were 
obtained from S. Freigang (Institute of  Pathology, University of  Bern). Eight to ten-week-old age- and 
sex-matched animals were used for all experiments. B16F10 melanoma and MC38 colon cancer cells 
were engrafted s.c. (2 × 105 cells) onto the left flank of  B6 mice on day 0. For certain experiments, a 
second contralateral tumor was induced s.c. in (5 × 105 cells) on day 5. Mice were inoculated with 
breast cancer tumors by injecting 4T1 cells (2 × 105 cells) into the mammary fat pads of  BALB/c mice. 
After randomization, mice were treated with intratumoral or intravenous (where indicated) injection of  
recombinant human IL-32γ (5 μg/mouse) or PBS into the primary tumor on day 7 and 11 while leaving 
the contralateral tumor untreated. For all tumor models, mice were euthanized between day 12 and 18 
after tumor inoculation (see Figure 4A) or when tumor volume exceeded 1000 mm3. Anti–PD-1 (RMP1-
14, Bio X Cell, BE0146) mAb was administered i.p. (200 μg) biweekly starting at day 3 after tumor induc-
tion. For depletion of  specific lymphocyte subsets, mice were treated i.p. with anti-CD8 antibody (200 
μg, clone 53-6.7, Bio X Cell, BE0004-1), anti-CD4 antibody (200 μg, clone GK1.5, Bio X Cell, BE0003-
1), or anti-NK1.1 antibody (200 μg, clone PK136, Bio X Cell, BE0036) every other day starting from day 
3 after tumor induction. Macrophages were depleted by administering an anti-CSF1R antibody (500 μg, 
clone AFS98, Bio X Cell, BE0213) every other day starting 5 days before tumor inoculation. Tumor size 
was measured in 2 dimensions using a digital caliper in a blinded fashion Tumor volume was calculated 
using the following formula V = (length × width2)/2 (44). For survival experiments, mice were eutha-
nized when the tumor volume reached 1000 mm3 or when ulcerations occurred. WBC and RBC counts 
were determined using a Sysmex KX-21N Automated Hematology Analyzer. All mice were housed in 
specific–pathogen free conditions in the Central Animal Facility of  the University of  Bern.
Flow cytometric analyses and cell sorting. To obtain single-cell suspensions for flow cytometry, tumors 
were mechanically dissociated and filtered twice through a 40 μM strainer (Thermo Fisher Scientific). 
The following antibodies against mouse antigens were used for flow cytometry: anti–IFN-γ (XMG1.2, 
BioLegend, 505830), anti-CD3ε (145-2C11, BioLegend, 100306), anti-CD3 (17A2, BioLegend, 100236), 
anti-CD4 (RM4-5, BioLegend, 100538), anti-CD8α (53-6.7, BioLegend, 100730), anti-CD45.2 (104, Bio-
Legend, 109830), anti-CD40 (3/23, BioLegend, 124624), anti-CD80 (16-10A1, BioLegend, 104708), anti-
H-2Kb (MHC class I, AF6-88.5, BioLegend, 116518), anti-CD11c (N418, BioLegend, 117336), and anti-
CD86 (GL-1, BioLegend, 105006). For human antigens, the following antibodies were used: anti-CD45RO 
(UCHL1, BioLegend, 304224), anti-CD45RA (JS-83, Thermo Fisher Scientific, 12-9979-42), anti-CD197 
(G043H7, BioLegend, 353226), anti-CD62L (DREG-56, Thermo Fisher Scientific, 47-0629-42), anti-
CD3 (OKT3, BioLegend, 317328), anti-CD4 (RPA-T4, BioLegend, 300518), anti-CD8 (SK1, BioLegend, 
344722), anti-IL32αβγδ (KU32-52, BioLegend, 513503), and anti-CD56 (REA196, BioLegend, 304611). 
The Zombie Aqua or UV Fixable Viability Kit (BioLegend, 423102 or 423108) was used to distinguish 
between live and dead cells in each experiment. PE-streptavidin (Thermo Fisher Scientific, SA10041) 
was used to detect biotinylated anti-IL32, whereas all other antibodies were directly conjugated to fluoro-
chromes. All the reagents mentioned above were purchased from BioLegend or Thermo Fisher Scientific. 
Prior to surface staining of  cells, Fc receptor blocking was performed with anti-mouse CD16/32 (2.4G2, 
generated in-house) for 15 minutes. Subsequently, cell surface markers were stained with antibodies in 
FACS buffer (PBS with 2% FBS and 1 mM EDTA) for 45 minutes on ice. Intracellular staining for IL-32 
and IFN-γ was performed using the eBioscience Foxp3/Transcription Factor Staining Buffer Set following 
the manufacturer’s protocols. Trp2 tetramers (iTAg Tetramer/PE H-2Kb TRP2) were obtained from MBL 
and added to the surface stain antibody cocktail. Samples were analyzed on BD LSRII and Beckman 
Coulter CytoFLEX S flow cytometers and data were processed using Flowjo (Tree Star). Naive and effector 
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CD4+ and CD8+ T cells were FACS purified using a Moflo Astrios EQ cell sorter (Beckman Coulter). Naive 
cells were defined as CD45RA+CD45RO–CCR7+CD62L+ and effector cells were identified as CD45RA+C-
D45RO–CCR7–CD62L– as previously defined (61).
Tumor cytokine bead array and chemokine ELISA. B16F10 melanomas were established and treated as 
described (see Figure 4A). On day 12, mice were sacrificed, and tumors and peripheral blood samples (car-
diac puncture) were collected. Tumors were homogenized in a lysis buffer (4 μl/mg) consisting of  PBS and 
0.05% Tween-20 as well as leupeptin (100 μM), aprotinin (10 μg/mL), and PMSF (200 μM). Lysis was per-
formed with the aid of  the QIAGEN TissueLyser II platform. Tumor lysates were centrifuged at 10,000g 
for 10 minutes at 4°C, and supernatants were collected, aliquoted, and stored in –80°C until analysis. Sera 
were obtained from blood by centrifugation in BD Microtainer blood collection tubes (BD SST). Protein 
concentrations of  tumor lysates were measured using Bradford protein quantification, and normalized 
samples and sera were submitted to Eve Technologies for cytokine array analysis (Mouse Cytokine Array/
Chemokine Array 44-plex) or measured using a CCL5 or CCL4 specific ELISA (Abcam). Cytokine protein 
concentration log2(pg/mL) were visualized using the heatmap3 package in R (62).
DNA isolation and TCRβ sequencing. On day 14 after tumor inoculation, B16F10 tumors and spleens 
were isolated. Genomic DNA was extracted using the DNeasy Blood and Tissue Kit (QIAGEN). TCRβ 
sequencing was performed using the ImmunoSEQ survey level assay (Adaptive Biotechnologies). Sequenc-
ing data was analyzed using the ImmunoSEQ analyzer (Adaptive Biotechnologies).
TCGA data collection and analysis. TCGA gene expression data as well as clinical information from all 
available cancer cohorts were obtained using GDCRNATools (63). Counts were normalized using default 
parameters of  the DESeq2 package in R (64). Gene expression of  IL-32 was correlated with gene expression 
of CD11c (ITGAX), CD86, CD80, and CD40 respectively, using Pearson correlation. For further analyses, 
samples were stratified in 2 groups according to their expression of  IL-32 (low and high) using the bottom 
and top quartiles. The mature DC gene signature was obtained from a list of  significantly upregulated genes 
induced in LPS plus IFN-γ matured human DC as described in a previous study (30). Bulk tumor RNA-
Seq data sets from all TCGA cohorts were scored for the mature DC and cDC1 (CLEC9A, XCR1, CLNK, 
BATF3) signatures using the singscore package in R (65). For cutaneous melanoma (SKCM), enrichment 
of  genes constituting the mature DC signature were visualized using the heatmap3 package in R (62). The 
association between IL32 mRNA expression and survival was assessed by Kaplan-Meier analysis using the 
survminer package in R (http://www.sthda.com/english/rpkgs/survminer/). GO term enrichment analy-
ses were performed using the clusterProfiler package in R (66). For the Kaplan-Meier survival plot in Figure 
1F, the survival time was calculated by subtracting the days from initial diagnosis to diagnosis of  the tumor 
used for RNA-Seq (“days_to_submitted_specimen_dx” taken from http://firebrowse.org/?cohort=SKCM, 
file “Merge_Clinical (MD5)“) from the overall survival time. The relative abundance of  immune and non-
immune cells was estimated from bulk tumor gene expression profiles from TCGA using quanTIseq (33). 
Furthermore, the relative proportions of  22 types of  infiltrating immune cell subsets were determined via 
the LM22 leukocyte signature matrix using CIBERSORT (34). A recommended P value threshold of  less 
than 0.05 on the P value for the global deconvolution of  each sample was applied (67).
Analysis of  GEO data sets. Publicly available microarray data sets were obtained from gene expression 
omnibus (GEO). Single-cell RNA-Seq data from CD45+ and CD45– FACS-purified cells from human 
melanoma samples was obtained from GSE72056 (35). Affymetrix arrays were batch normalized and 
processed using the fRMA package in R (68). Samples with a generalized normalized unscaled stan-
dard error (GNUSE) ≥1.25 were excluded. RNA-Seq data from patients with nivolumab treatment were 
obtained from GSE91061 and normalized using the DESeq2 package in R (49, 64). NanoString samples 
from patient biopsies with pembrolizumab treatment were obtained from GSE123728 and normalized 
with nSolver analysis software 4.0 (NanoString) (50).
NanoString mRNA profiling. FACS-purified human PBMC subsets from healthy human donors were lysed 
in 10 μl Buffer RLT (QIAGEN) containing 1% 2-mercaptoethanol (MilliporeSigma) diluted 1:2 in PBS. Sub-
sequently, 5 μl lysate was directly used for mRNA profiling. Human melanoma cells as well as murine BMDC 
and BMDM were lysed in 250 μL RLT buffer as described above and purified using RNeasy Mini Spin 
Columns (QIAGEN) according the manufacturer’s protocol. Prior to measurement, the RNA concentration 
of  all samples was normalized. Human cell lysates were assessed for the expression of  key immunological 
genes using NanoString Human Immunology Panel V2. Mouse BMDC lysates were transcriptionally ana-
lyzed using the Mouse Immunology Panel. All profiling was performed using the nCounter Digital Analyzer 
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(NanoString Technologies). Data quality control, normalization, and evaluation were performed using the 
nSolver analysis software 4.0.
Immunohistochemistry and immunofluorescence. All samples were obtained from patients with resect-
ed primary or metastatic melanoma. Serial sections were cut from formalin-fixed, paraffin-embedded 
tissue blocks. Murine B16F10 tumors were established and treated as in Figure 4A and embedded in 
paraffin on day 14. For CD8+ T cell detection, human melanoma and B16F10 tissue sections were 
processed for deparaffinization, target retrieval, and immunohistochemical labeling using the in-house 
established fully automated Bond RX system (Leica Biosystems). Human CD8 antigen was detected 
using a mouse anti-human CD8 antibody (C8/144) while mouse CD8 antigen was detected using a rat 
polyclonal anti-mouse CD8 antibody (Dianova) and alkaline phosphatase. For IL-32 detection, human 
melanoma tissue sections were deparaffinized using Neo-Clear (Merck Millipore) and graded ethanol 
washing, followed by antigen retrieval (DAKO Target Retrieval Solution pH6) in an autoclave (Prestige 
Medical). IL-32 was detected using a mouse anti-human IL-32 antibody (KU32-09), EnVision+ Sys-
tem- HRP Labelled Polymer anti-mouse (Dako), and an AEC Staining Kit (MilliporeSigma). Counter-
staining was performed with hematoxylin dye. Whole-slide images were acquired using a Pannoramic 
250 Flash II (3D Histech). Immunofluorescence labeling for IL-32 (KU32-52, BioLegend), CD3 (SP7, 
Abcam), CD8 (C8/144B, Biosystems), and DAPI was performed using the Opal 4-Color Manual IHC 
kit (Akoya Biosciences) according to the manufacturer’s protocol. Cell quantification was performed 
with the assistance of  the image analysis software QuPath (69).
Phospho-kinase array. Human monocytes were isolated as described above using the EasySep Human 
Monocyte Enrichment Kit without CD16 Depletion (STEMCELL Technologies). Monocytes were 
treated with IL-32γ (200 ng/mL) and incubated at 37°C for 20 minutes. Sample preparation and array 
procedure was performed according to the manufacturer’s protocol using the Proteome Profiler Phos-
pho-Kinase Array (R&D Systems). Signal measurement was performed using the ChemiDoc Touch 
Imaging System (Bio-Rad) and quantified using the Protein Array Analyzer tool in ImageJ (NIH).
Statistics. Statistical analyses were performed using GraphPad Prism 7.0 or R. Statistical significance 
was determined as described in the figure legends, with 2-way ANOVA followed by Šidák’s multiple com-
parisons test and 2-tailed Student’s t test. R2 was calculated as follows: (Pearson correlation coefficient)2. 
All measurements were taken from distinct samples; n = biological independent replicates. P < 0.05 was 
considered significant.
Study approval. Patient samples used in this study were collected from patients with metastatic mel-
anoma. Human melanoma tissue was collected in accordance with guidelines of  the Cantonal Ethics 
Committee (KEK) in Bern under approved protocols (KEK ID: 2017-02246). All animal experiments 
were performed in accordance with federal regulations and approved by the Cantonal Veterinary Office.
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